Associated High Confidence AOPs |
---|
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:4 | Ecdysone receptor agonism leading to incomplete ecdysis associated mortality | Unclassified | - | 0.2 | KE:1264 | Increase, Nuclear receptor E75b gene expression |
KE:1265 | Increase, Fushi tarazu factor-1 gene expression | |||||
AOP:7 | Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female | Reproductive System Disease; Endocrine System Disease; Reproductive System Disease | Under Review | 0.4 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |||||
AOP:15 | Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations | Genetic Disease | WPHA/WNT Endorsed | 0.25 | KE:155 | Inadequate DNA repair |
AOP:16 | Acetylcholinesterase inhibition leading to acute mortality | Unclassified | Under Development | 0.14 | KE:445 | Respiratory distress/arrest |
AOP:18 | PPARα activation in utero leading to impaired fertility in males | Reproductive System Disease | Under Review | 0.5 | KE:1690 | Decrease, circulating testosterone levels |
KE:413 | Reduction, Testosterone synthesis in Leydig cells | |||||
KE:266 | Decrease, Steroidogenic acute regulatory protein (STAR) | |||||
KE:289 | Decrease, Translocator protein (TSPO) | |||||
AOP:23 | Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) | Unclassified | WPHA/WNT Endorsed | 0.4 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:274 | Reduction, Testosterone synthesis by ovarian theca cells | |||||
KE:285 | Reduction, Vitellogenin synthesis in liver | |||||
KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |||||
AOP:25 | Aromatase inhibition leading to reproductive dysfunction | Unclassified | WPHA/WNT Endorsed | 0.38 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:285 | Reduction, Vitellogenin synthesis in liver | |||||
KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |||||
AOP:30 | Estrogen receptor antagonism leading to reproductive dysfunction | Unclassified | Under Review | 0.17 | KE:285 | Reduction, Vitellogenin synthesis in liver |
AOP:36 | Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.12 | KE:140 | Decreased, HSD17B10 expression |
AOP:37 | PPARα activation leading to hepatocellular adenomas and carcinomas in rodents | Cancer; Gastrointestinal System Disease | Under Development | 0.2 | KE:716 | Increase, cell proliferation (hepatocytes) |
AOP:39 | Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response | Respiratory System Disease | Under Development | 0.2 | KE:272 | Activation/Proliferation, T-cells |
AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary System Disease | WPHA/WNT Endorsed | 0.2 | KE:272 | Activation/Proliferation, T-cells |
AOP:43 | Disruption of VEGFR Signaling Leading to Developmental Defects | Unclassified | WPHA/WNT Endorsed | 0.2 | KE:28 | Reduction, Angiogenesis |
AOP:58 | NR1I3 (CAR) suppression leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.31 | KE:458 | Increased, De Novo FA synthesis |
KE:463 | Up Regulation, FAS | |||||
KE:54 | Up Regulation, CD36 | |||||
KE:454 | Increased, Triglyceride formation | |||||
KE:462 | Up Regulation, SCD-1 | |||||
AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive System Disease | - | 0.57 | KE:413 | Reduction, Testosterone synthesis in Leydig cells |
KE:1690 | Decrease, circulating testosterone levels | |||||
KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells | |||||
KE:520 | Decreased sperm quantity or quality in the adult, Decreased fertility | |||||
AOP:73 | Xenobiotic Inhibition of Dopamine-beta-Hydroxylase and subsequent reduced fecundity | Unclassified | - | 0.23 | KE:531 | Decreased, LH Surge |
KE:10059 | Decreased LH surge for 24 hours | |||||
KE:529 | Decreased, GnRH cfos activity | |||||
AOP:77 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 | Unclassified | - | 0.29 | KE:177 | Mitochondrial dysfunction |
KE:341 | Impairment, Learning and memory | |||||
AOP:78 | Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 | Unclassified | - | 0.38 | KE:177 | Mitochondrial dysfunction |
KE:386 | Decrease of neuronal network function | |||||
KE:341 | Impairment, Learning and memory | |||||
AOP:79 | Nicotinic acetylcholine receptor activation contributes to impaired hive thermoregulation and leads to colony loss/failure | Unclassified | - | 0.2 | KE:177 | Mitochondrial dysfunction |
AOP:80 | Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure | Unclassified | - | 0.25 | KE:177 | Mitochondrial dysfunction |
KE:664 | Overwhelmed, Mitochondrial DNA repair mechanisms | |||||
AOP:87 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure | Unclassified | - | 0.25 | KE:177 | Mitochondrial dysfunction |
KE:341 | Impairment, Learning and memory | |||||
AOP:88 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste | Unclassified | - | 0.14 | KE:341 | Impairment, Learning and memory |
AOP:89 | Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:90 | Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 | Unclassified | - | 0.25 | KE:386 | Decrease of neuronal network function |
KE:341 | Impairment, Learning and memory | |||||
AOP:94 | Sodium channel inhibition leading to congenital malformations | Unclassified | - | 0.17 | KE:445 | Respiratory distress/arrest |
AOP:102 | Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition | Reproductive System Disease | - | 0.1 | KE:690 | Reduced, Luteinizing hormone (LH), plasma |
AOP:103 | Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint | Reproductive System Disease | - | 0.1 | KE:690 | Reduced, Luteinizing hormone (LH), plasma |
AOP:104 | Altered ion channel activity leading impaired heart function | Unclassified | - | 0.25 | KE:698 | Altered, Action Potential |
AOP:105 | Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary System Disease | - | 0.33 | KE:709 | Increase, Cytotoxicity (renal tubular cell) |
KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) | |||||
AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal System Disease | Under Review | 0.4 | KE:1214 | Altered gene expression specific to CAR activation, Hepatocytes |
KE:716 | Increase, cell proliferation (hepatocytes) | |||||
AOP:108 | Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.17 | KE:769 | Increase, Oxidative metabolism |
AOP:109 | Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) | Cancer; Respiratory System Disease | - | 0.2 | KE:734 | Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.43 | KE:739 | Increase, Hypertrophy and proliferation (follicular cell) |
KE:1023 | Increased, Thyroid-stimulating hormone (TSH) | |||||
KE:281 | Thyroxine (T4) in serum, Decreased | |||||
AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive System Disease; Cancer | - | 0.17 | KE:749 | Decreased, Progesterone from corpus luteum |
AOP:114 | HPPD inhibition leading to corneal papillomas and carcinomas (in rat) | Cancer | - | 0.33 | KE:777 | Increase, Inflammation (corneal cells) |
KE:778 | Increase, Regenerative cell proliferation (corneal cells) | |||||
AOP:115 | Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) | Cancer | - | 0.4 | KE:149 | Increase, Inflammation |
KE:781 | Increase, Regenerative cell proliferation (forestomach epithelial cells) | |||||
AOP:116 | Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary System Disease | - | 0.25 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
AOP:117 | Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | Under Development | 0.25 | KE:716 | Increase, cell proliferation (hepatocytes) |
AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.43 | KE:739 | Increase, Hypertrophy and proliferation (follicular cell) |
KE:1023 | Increased, Thyroid-stimulating hormone (TSH) | |||||
KE:281 | Thyroxine (T4) in serum, Decreased | |||||
AOP:120 | Inhibition of 5α-reductase leading to Leydig cell tumors (in rat) | Cancer; Reproductive System Disease | - | 0.2 | KE:1690 | Decrease, circulating testosterone levels |
AOP:122 | Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation | Unclassified | - | 0.4 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:799 | Increased, HIF-1 heterodimer | |||||
KE:285 | Reduction, Vitellogenin synthesis in liver | |||||
KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |||||
AOP:123 | Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription | Unclassified | - | 0.45 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:802 | Increased, HIF-1 alpha transcription | |||||
KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |||||
KE:285 | Reduction, Vitellogenin synthesis in liver | |||||
KE:799 | Increased, HIF-1 heterodimer | |||||
AOP:126 | Alpha-noradrenergic antagonism leads to reduced fecundity via delayed ovulation | Unclassified | - | 0.23 | KE:531 | Decreased, LH Surge |
KE:10059 | Decreased LH surge for 24 hours | |||||
KE:529 | Decreased, GnRH cfos activity | |||||
AOP:130 | Phospholipase A2 (LPLA2) inhibitors leading to hepatotoxicity | Gastrointestinal System Disease | Under Development | 0.55 | KE:831 | Disturbance, Lysosomal function |
KE:833 | Occurrence, Cytoplasmic vacuolization (hepatocyte) | |||||
KE:177 | Mitochondrial dysfunction | |||||
KE:835 | Occurrence, Ballooning degeneration (hepatocyte) | |||||
KE:836 | Occurrence, Cytoplasmic vacuolization (Bile duct cell) | |||||
KE:837 | Occurrence, Cytoplasmic vacuolization (kupffer cell) | |||||
AOP:131 | Aryl hydrocarbon receptor activation leading to uroporphyria | Inherited Metabolic Disorder | WPHA/WNT Endorsed | 0.17 | KE:850 | Induction, CYP1A2/CYP1A5 |
AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign Neoplasm; Respiratory System Disease | Under Review | 0.29 | KE:870 | Increase, Cell Proliferation |
KE:868 | Increase, Tissue Degeneration, Necrosis & Atrophy | |||||
AOP:144 | Endocytic lysosomal uptake leading to liver fibrosis | Gastrointestinal System Disease | Under Review | 0.44 | KE:898 | Disruption, Lysosome |
KE:68 | Accumulation, Collagen | |||||
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:177 | Mitochondrial dysfunction | |||||
AOP:155 | Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
AOP:156 | Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
AOP:157 | Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
AOP:158 | Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.25 | KE:281 | Thyroxine (T4) in serum, Decreased |
KE:1003 | Decreased, Triiodothyronine (T3) | |||||
AOP:164 | Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse | Cancer; Reproductive System Disease | - | 0.17 | KE:1042 | Proliferation/Clonal Expansion, smooth muscle |
AOP:175 | Thyroperoxidase inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:281 | Thyroxine (T4) in serum, Decreased |
AOP:176 | Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.2 | KE:281 | Thyroxine (T4) in serum, Decreased |
AOP:188 | Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.2 | KE:281 | Thyroxine (T4) in serum, Decreased |
AOP:189 | Type I iodothyronine deiodinase (DIO1) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.5 | KE:1116 | Decreased, Triiodothyronine (T3) in tissues |
KE:1003 | Decreased, Triiodothyronine (T3) | |||||
AOP:190 | Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.33 | KE:1116 | Decreased, Triiodothyronine (T3) in tissues |
KE:1023 | Increased, Thyroid-stimulating hormone (TSH) | |||||
AOP:192 | Pendrin inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:281 | Thyroxine (T4) in serum, Decreased |
AOP:193 | Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:281 | Thyroxine (T4) in serum, Decreased |
AOP:194 | Hepatic nuclear receptor activation leading to altered amphibian metamorphosis | Unclassified | - | 0.33 | KE:1158 | Increased, Hepatic thyroid hormone uptake/transport |
KE:281 | Thyroxine (T4) in serum, Decreased | |||||
AOP:213 | Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:218 | Inhibition of CYP7B activity leads to decreased reproductive success via decreased locomotor activity | Unclassified | - | 0.33 | KE:1141 | Decreased, Reproductive Success |
KE:1389 | Locomotor activity, decreased | |||||
AOP:219 | Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior | Unclassified | - | 0.33 | KE:1141 | Decreased, Reproductive Success |
KE:1390 | Sexual behavior, decreased | |||||
AOP:227 | NSAID induced PTGS1 inactivation to gastric ulcer | Gastrointestinal System Disease | - | 0.14 | KE:1403 | Reduced, platelet aggregation |
AOP:271 | Inhibition of thyroid peroxidase leading to impaired fertility in fish | Unclassified | Under Development | 0.2 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
AOP:276 | Inhibition of complex I of the electron transport chain leading to chemical induced Fanconi syndrome | Urinary System Disease | - | 0.17 | KE:887 | Inhibition, NADH-ubiquinone oxidoreductase (complex I) |
AOP:280 | α-diketone-induced bronchiolitis obliterans | Musculoskeletal System Disease; Respiratory System Disease | - | 0.14 | KE:149 | Increase, Inflammation |
AOP:288 | Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) | Endocrine System Disease | - | 0.12 | KE:1690 | Decrease, circulating testosterone levels |
AOP:289 | Inhibition of 5α-reductase leading to impaired fecundity in female fish | Unclassified | Under Development | 0.17 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
AOP:297 | Inhibition of retinaldehyde dehydrogenase leads to population decline | Unclassified | Under Development | 0.17 | KE:1643 | Altered, Visual function |
AOP:299 | Deposition of energy leading to population decline via DNA oxidation and follicular atresia | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:305 | 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | 0.2 | KE:286 | Altered, Transcription of genes by the androgen receptor |
AOP:306 | Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | 0.25 | KE:286 | Altered, Transcription of genes by the androgen receptor |
AOP:309 | Luteinizing hormone receptor antagonism leading to reproductive dysfunction | Unclassified | - | 0.29 | KE:1693 | Reduction, Plasma progesterone concentration |
KE:1692 | Reduction, Progesterone synthesis | |||||
AOP:310 | Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR | Unclassified | - | 0.25 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:285 | Reduction, Vitellogenin synthesis in liver | |||||
KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |||||
AOP:311 | Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:315 | Inhibition of JAK3 leading to impairment of T-Cell Dependent Antibody Response | Immune System Disease | Under Development | 0.2 | KE:1716 | Blockade of STAT5 phosphorylation |
AOP:320 | Binding of SARS-CoV-2 to ACE2 receptor leading to acute respiratory distress associated mortality | Unclassified | Under Development | 0.11 | KE:1750 | Increased inflammatory immune responses |
AOP:321 | Reduced environmental pH leading to thinner shells in Mytilus edulis | Unclassified | - | 0.18 | KE:592 | Reduced, survival |
KE:10042 | Abnormal development | |||||
AOP:344 | Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring | Unclassified | Under Development | 0.25 | KE:286 | Altered, Transcription of genes by the androgen receptor |
AOP:345 | Androgen receptor (AR) antagonism leading to decreased fertility in females | Endocrine System Disease; Reproductive System Disease; Reproductive System Disease | Under Development | 0.17 | KE:286 | Altered, Transcription of genes by the androgen receptor |
AOP:346 | Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation | Unclassified | WPHA/WNT Endorsed | 0.4 | KE:1789 | Reduction, 17beta-estradiol synthesis by the undifferentiated gonad |
KE:1790 | Increased, Differentiation to Testis | |||||
AOP:348 | Inhibition of 11β-Hydroxysteroid Dehydrogenase leading to decreased population trajectory | Unclassified | Under Development | 0.2 | KE:1758 | Impaired, Spermatogenesis |
AOP:349 | Inhibition of 11β-hydroxylase leading to decresed population trajectory | Unclassified | Under Development | 0.25 | KE:1836 | Decreased plasma Cortisol level |
KE:1835 | Cortisol and 11β-(OH) testosterone decreased | |||||
AOP:362 | Immune mediated hepatitis | Gastrointestinal System Disease; Immune System Disease | - | 0.12 | KE:177 | Mitochondrial dysfunction |
AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | 0.5 | KE:1877 | Altered, retinal layer structure |
KE:1643 | Altered, Visual function | |||||
KE:281 | Thyroxine (T4) in serum, Decreased | |||||
KE:1003 | Decreased, Triiodothyronine (T3) | |||||
AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.5 | KE:1643 | Altered, Visual function |
KE:1878 | Decreased, Eye size | |||||
KE:281 | Thyroxine (T4) in serum, Decreased | |||||
KE:1003 | Decreased, Triiodothyronine (T3) | |||||
AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.38 | KE:1643 | Altered, Visual function |
KE:281 | Thyroxine (T4) in serum, Decreased | |||||
KE:1003 | Decreased, Triiodothyronine (T3) | |||||
AOP:366 | Competitive binding to thyroid hormone carrier protein transthyretin (TTR) leading to altered amphibian metamorphosis | Unclassified | - | 0.29 | KE:1158 | Increased, Hepatic thyroid hormone uptake/transport |
KE:281 | Thyroxine (T4) in serum, Decreased | |||||
AOP:367 | Competitive binding to thyroid hormone carrier protein thyroid binding globulin (TBG) leading to altered amphibian metamorphosis | Unclassified | - | 0.29 | KE:1158 | Increased, Hepatic thyroid hormone uptake/transport |
KE:281 | Thyroxine (T4) in serum, Decreased | |||||
AOP:372 | Androgen receptor antagonism leading to testicular cancer | Endocrine System Disease; Reproductive System Disease; Cancer | - | 0.2 | KE:286 | Altered, Transcription of genes by the androgen receptor |
AOP:374 | Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis | Nervous System Disease | Under Development | 0.5 | KE:188 | Neuroinflammation |
KE:352 | N/A, Neurodegeneration | |||||
AOP:376 | Androgen receptor agonism leading to male-biased sex ratio | Unclassified | WPHA/WNT Endorsed | 0.25 | KE:1790 | Increased, Differentiation to Testis |
AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular System Disease | Under Development | 0.14 | KE:1869 | Diminished protective oxidative stress response |
AOP:383 | Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis | Gastrointestinal System Disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:386 | Deposition of ionizing energy leading to population decline via inhibition of photosynthesis | Reproductive System Disease | - | 0.12 | KE:1115 | Increase, Reactive oxygen species |
AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive System Disease | - | 0.25 | KE:40 | Decrease, Mitochondrial ATP production |
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:397 | Bulky DNA adducts leading to mutations | Genetic Disease | Under Development | 0.33 | KE:155 | Inadequate DNA repair |
AOP:399 | Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Unclassified | - | 0.38 | KE:1821 | Decrease, Cell proliferation |
KE:1643 | Altered, Visual function | |||||
KE:1878 | Decreased, Eye size | |||||
AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.38 | KE:1115 | Increase, Reactive oxygen species |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:870 | Increase, Cell Proliferation | |||||
AOP:413 | Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure | Unclassified | - | 0.67 | KE:1115 | Increase, Reactive oxygen species |
KE:759 | Increased, Kidney Failure | |||||
KE:1607 | Increase, Necrosis | |||||
KE:1445 | Increase, Lipid peroxidation | |||||
AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic System Disease; Cancer | - | 0.27 | KE:870 | Increase, Cell Proliferation |
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:155 | Inadequate DNA repair | |||||
AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital Nervous System Abnormality; Nervous System Disease | - | 0.14 | KE:1262 | Apoptosis |
AOP:444 | Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability | Unclassified | - | 0.22 | KE:1365 | Increase, Apoptosis |
KE:1392 | Oxidative Stress | |||||
AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous System Disease | - | 0.43 | KE:618 | Decreased, Neuronal network function in adult brain |
KE:352 | N/A, Neurodegeneration | |||||
KE:1392 | Oxidative Stress | |||||
AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | 0.33 | KE:1821 | Decrease, Cell proliferation |
KE:1262 | Apoptosis | |||||
KE:2040 | Decrease, GLI1/2 target gene expression | |||||
AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.12 | KE:2050 | Increase, developmental abnormalities |
AOP:467 | Knickkopf leading to mortality | Unclassified | - | 0.11 | KE:2050 | Increase, developmental abnormalities |
AOP:470 | Deposition of energy leads to abnormal vascular remodeling | Cardiovascular System Disease | Under Review | 0.38 | KE:2244 | Altered Stress Response Signaling |
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:1392 | Oxidative Stress | |||||
AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous System Disease; Monogenic Disease | Under Review | 0.4 | KE:870 | Increase, Cell Proliferation |
KE:1636 | Increase, Chromosomal aberrations | |||||
KE:155 | Inadequate DNA repair | |||||
KE:1392 | Oxidative Stress | |||||
AOP:479 | Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress | Cardiovascular System Disease; Thoracic Disease | Under Development | 0.29 | KE:177 | Mitochondrial dysfunction |
KE:1392 | Oxidative Stress | |||||
AOP:480 | Mitochondrial complexes inhibition leading to heart failure via decreased ATP production | Cardiovascular System Disease; Thoracic Disease | Under Development | 0.4 | KE:40 | Decrease, Mitochondrial ATP production |
KE:177 | Mitochondrial dysfunction | |||||
AOP:492 | Glutathione conjugation leading to reproductive dysfunction via oxidative stress | Reproductive System Disease | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1445 | Increase, Lipid peroxidation | |||||
AOP:496 | Androgen receptor agonism leading to reproduction dysfunction (in zebrafish) | Unclassified | - | 0.3 | KE:1690 | Decrease, circulating testosterone levels |
KE:286 | Altered, Transcription of genes by the androgen receptor | |||||
KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |||||
AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | 0.33 | KE:2251 | Estradiol availability, increased |
AOP:507 | Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway | Cardiovascular System Disease | - | 0.17 | KE:1392 | Oxidative Stress |
AOP:509 | Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction | Cardiovascular System Disease | - | 0.43 | KE:177 | Mitochondrial dysfunction |
KE:1365 | Increase, Apoptosis | |||||
KE:1392 | Oxidative Stress | |||||
AOP:510 | Demethylation of PPAR promotor leading to vascular disrupting effects | Cardiovascular System Disease | - | 0.1 | KE:1392 | Oxidative Stress |
AOP:518 | Liver X Receptor (LXR) activation leads to liver steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.2 | KE:89 | Synthesis, De Novo Fatty Acid (FA) |
AOP:524 | Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals | Immune System Disease; Gastrointestinal System Disease | - | 0.11 | KE:2255 | Innate immune response, activation |
AOP:529 | Perfluorooctanesulfonic acid (PFOS) binding to peroxisome proliferator-activated receptors (PPARs) causes dysregulation of lipid metabolism and subsequent liver steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.12 | KE:2224 | Dysregulation of transcriptional expression within PPAR signaling network |
AOP:530 | Endocytotic lysosomal uptake leads to intestinal barrier disruption | Gastrointestinal System Disease | - | 0.4 | KE:177 | Mitochondrial dysfunction |
KE:898 | Disruption, Lysosome | |||||
AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | 0.17 | KE:307 | Increase, Vitellogenin synthesis in liver |
AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.4 | KE:307 | Increase, Vitellogenin synthesis in liver |
KE:364 | Impaired development of, Reproductive organs | |||||
AOP:544 | Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation | Nervous System Disease | - | 0.17 | KE:149 | Increase, Inflammation |
AOP:549 | Aromatase inhibition leads to reproductive toxicity (including growth and developmental toxicity) in adult female zebrafish | Unclassified | - | 0.12 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | 0.4 | KE:2251 | Estradiol availability, increased |
KE:2294 | Plasma estradiol, increased | |||||
AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive System Disease; Endocrine System Disease | - | 0.17 | KE:1262 | Apoptosis |
AOP:564 | DBDPE-induced inhibition of mitochondrial complex Ⅰ leading to population decline via neurotoxicity and metabotoxicity. | Unclassified | - | 0.18 | KE:40 | Decrease, Mitochondrial ATP production |
KE:2151 | Disruption, neurotransmitter release |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:3 | Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits | Nervous System Disease | WPHA/WNT Endorsed | 0.57 | KE:177 | Mitochondrial dysfunction |
KE:896 | Parkinsonian motor deficits | |||||
KE:188 | Neuroinflammation | |||||
KE:887 | Inhibition, NADH-ubiquinone oxidoreductase (complex I) | |||||
AOP:6 | Antagonist binding to PPARα leading to body-weight loss | Symptom | WPHA/WNT Endorsed | 0.25 | KE:863 | Increased, Catabolism of Muscle Protein |
KE:864 | Decreased, Body Weight | |||||
AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous System Disease; Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.62 | KE:52 | Decreased, Calcium influx |
KE:188 | Neuroinflammation | |||||
KE:352 | N/A, Neurodegeneration | |||||
KE:341 | Impairment, Learning and memory | |||||
KE:381 | Reduced levels of BDNF | |||||
AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.4 | KE:386 | Decrease of neuronal network function |
KE:381 | Reduced levels of BDNF | |||||
KE:52 | Decreased, Calcium influx | |||||
KE:341 | Impairment, Learning and memory | |||||
AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.5 | KE:386 | Decrease of neuronal network function |
KE:1392 | Oxidative Stress | |||||
KE:188 | Neuroinflammation | |||||
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:341 | Impairment, Learning and memory | |||||
AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive System Disease | - | 0.4 | KE:286 | Altered, Transcription of genes by the androgen receptor |
KE:337 | N/A, Impairment of reproductive capacity | |||||
AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | 0.6 | KE:317 | Altered, Cardiovascular development/function |
KE:1269 | Increase, COX-2 expression | |||||
KE:947 | Increase, Early Life Stage Mortality | |||||
AOP:28 | Cyclooxygenase inhibition leading reproductive failure | Reproductive System Disease | - | 0.33 | KE:49 | Reduction, Ca and HCO3 transport to shell gland |
KE:253 | N/A, Reproductive failure | |||||
AOP:34 | LXR activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.38 | KE:345 | N/A, Liver Steatosis |
KE:177 | Mitochondrial dysfunction | |||||
KE:54 | Up Regulation, CD36 | |||||
KE:89 | Synthesis, De Novo Fatty Acid (FA) | |||||
KE:258 | Activation, SCD-1 | |||||
AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | WPHA/WNT Endorsed | 0.5 | KE:757 | Hippocampal anatomy, Altered |
KE:402 | Cognitive function, decreased | |||||
KE:281 | Thyroxine (T4) in serum, Decreased | |||||
KE:756 | Hippocampal gene expression, Altered | |||||
AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.67 | KE:389 | Increased, Intracellular Calcium overload |
KE:177 | Mitochondrial dysfunction | |||||
KE:618 | Decreased, Neuronal network function in adult brain | |||||
KE:188 | Neuroinflammation | |||||
KE:352 | N/A, Neurodegeneration | |||||
KE:341 | Impairment, Learning and memory | |||||
AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.4 | KE:386 | Decrease of neuronal network function |
KE:381 | Reduced levels of BDNF | |||||
KE:281 | Thyroxine (T4) in serum, Decreased | |||||
KE:341 | Impairment, Learning and memory | |||||
AOP:91 | Sodium channel inhibition leading to reduced survival | Unclassified | - | 0.17 | KE:592 | Reduced, survival |
AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | 0.43 | KE:636 | Decreased, survival |
KE:341 | Impairment, Learning and memory | |||||
KE:635 | Decreased, locomotion | |||||
AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive System Disease | - | 0.5 | KE:330 | Decrease, Fertility |
KE:1690 | Decrease, circulating testosterone levels | |||||
KE:807 | Decreased, cholesterol | |||||
AOP:128 | Kidney dysfunction by decreased thyroid hormone | Urinary System Disease | Under Development | 0.55 | KE:821 | Decreased, Sodium reabsorption |
KE:819 | Decreased, Glomerular filtration | |||||
KE:281 | Thyroxine (T4) in serum, Decreased | |||||
KE:814 | Occurrence, Kidney toxicity | |||||
KE:825 | Decreased, Renal ability to dilute urine | |||||
KE:818 | Occurrence, Cytoplasmic vacuolization (Renal tubule) | |||||
AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.44 | KE:757 | Hippocampal anatomy, Altered |
KE:402 | Cognitive function, decreased | |||||
KE:281 | Thyroxine (T4) in serum, Decreased | |||||
KE:756 | Hippocampal gene expression, Altered | |||||
AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | 0.5 | KE:885 | Increase, Cancer |
KE:155 | Inadequate DNA repair | |||||
AOP:148 | EGFR Activation Leading to Decreased Lung Function | Respiratory System Disease | Under Development | 0.5 | KE:1250 | Decrease, Lung function |
KE:962 | Increase, Mucin production | |||||
AOP:149 | Peptide Oxidation Leading to Hypertension | Cardiovascular System Disease | Under Development | 0.4 | KE:927 | KE1 : S-Glutathionylation, eNOS |
KE:937 | KE7 : Impaired, Vasodilation | |||||
KE:952 | Hypertension | |||||
KE:933 | KE6 : Depletion, Nitric Oxide | |||||
AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | 0.43 | KE:317 | Altered, Cardiovascular development/function |
KE:947 | Increase, Early Life Stage Mortality | |||||
KE:948 | reduced production, VEGF | |||||
AOP:151 | AhR activation leading to preeclampsia | Cardiovascular System Disease | Under Development | 0.29 | KE:1893 | increase, Preeclampsia |
KE:948 | reduced production, VEGF | |||||
AOP:173 | Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | WPHA/WNT Endorsed | 0.38 | KE:68 | Accumulation, Collagen |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1458 | Pulmonary fibrosis | |||||
AOP:196 | Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation | Respiratory System Disease | - | 0.22 | KE:1226 | Increased Respiratory irritability and Chronic Cough, |
KE:1218 | Opening of calcium channel, Calcium influx | |||||
AOP:203 | 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline | Reproductive System Disease | - | 0.12 | KE:1141 | Decreased, Reproductive Success |
AOP:205 | AOP from chemical insult to cell death | Unclassified | - | 0.5 | KE:1263 | Necrosis |
KE:177 | Mitochondrial dysfunction | |||||
KE:1262 | Apoptosis | |||||
AOP:206 | Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.33 | KE:149 | Increase, Inflammation |
KE:1276 | Lung fibrosis | |||||
AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive System Disease | WPHA/WNT Endorsed | 0.5 | KE:1506 | Testicular atrophy |
KE:1262 | Apoptosis | |||||
KE:1503 | Histone acetylation, increase | |||||
AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.8 | KE:1393 | Hepatocytotoxicity |
KE:1394 | Induction, persistent proliferation/sustained proliferation | |||||
KE:1395 | Liver Cancer | |||||
KE:1392 | Oxidative Stress | |||||
AOP:237 | Substance interaction with lung resident cell membrane components leading to atherosclerosis | Cardiovascular System Disease | Under Development | 0.2 | KE:1443 | Atherosclerosis |
AOP:241 | Latent Transforming Growth Factor beta1 activation leads to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | - | 0.33 | KE:68 | Accumulation, Collagen |
KE:1458 | Pulmonary fibrosis | |||||
AOP:242 | Inhibition of lysyl oxidase leading to enhanced chronic fish toxicity | Unclassified | - | 0.12 | KE:636 | Decreased, survival |
AOP:245 | Reduction in photophosphorylation leading to growth inhibition in aquatic plants | Unclassified | - | 0.18 | KE:40 | Decrease, Mitochondrial ATP production |
KE:1521 | Decrease, Growth | |||||
AOP:256 | Inhibition of mitochondrial DNA polymerase gamma leading to kidney toxicity | Urinary System Disease | Under Development | 0.6 | KE:709 | Increase, Cytotoxicity (renal tubular cell) |
KE:177 | Mitochondrial dysfunction | |||||
KE:814 | Occurrence, Kidney toxicity | |||||
AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous System Disease | - | 0.29 | KE:1514 | Neurodegeneration |
KE:1392 | Oxidative Stress | |||||
AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | 0.17 | KE:10013 | Impaired growth and development |
AOP:270 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired locomotor activity | Unclassified | - | 0.12 | KE:10016 | Impaired locomotor activity |
AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | 0.57 | KE:870 | Increase, Cell Proliferation |
KE:1556 | Increase, lung cancer | |||||
KE:155 | Inadequate DNA repair | |||||
KE:1636 | Increase, Chromosomal aberrations | |||||
AOP:275 | Histone deacetylase inhibition leads to neural tube defects | Neural Tube Defect | - | 0.8 | KE:1561 | Neural tube defects |
KE:1503 | Histone acetylation, increase | |||||
KE:1560 | Altered differentiation | |||||
KE:1239 | Altered, Gene Expression | |||||
AOP:278 | IKK complex inhibition leading to liver injury | Unclassified | - | 0.12 | KE:1549 | Liver Injury |
AOP:281 | Acetylcholinesterase Inhibition Leading to Neurodegeneration | Nervous System Disease | - | 0.2 | KE:389 | Increased, Intracellular Calcium overload |
KE:352 | N/A, Neurodegeneration | |||||
AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | 0.75 | KE:1821 | Decrease, Cell proliferation |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
KE:1521 | Decrease, Growth | |||||
AOP:287 | Mitochondrial complex III antagonism leading to growth inhibition (2) | Unclassified | - | 0.5 | KE:1771 | Decrease, Adenosine triphosphate pool |
KE:1521 | Decrease, Growth | |||||
AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | 0.75 | KE:1821 | Decrease, Cell proliferation |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
KE:1521 | Decrease, Growth | |||||
AOP:291 | Mitochondrial ATP synthase antagonism leading to growth inhibition (2) | Unclassified | - | 0.5 | KE:1771 | Decrease, Adenosine triphosphate pool |
KE:1521 | Decrease, Growth | |||||
AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.33 | KE:1493 | Increased Pro-inflammatory mediators |
KE:1193 | N/A, Breast Cancer | |||||
KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | |||||
AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.33 | KE:1493 | Increased Pro-inflammatory mediators |
KE:1193 | N/A, Breast Cancer | |||||
KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | |||||
AOP:296 | Oxidative DNA damage leading to chromosomal aberrations and mutations | Genetic Disease; Chromosomal Disease | WPHA/WNT Endorsed | 0.4 | KE:155 | Inadequate DNA repair |
KE:1636 | Increase, Chromosomal aberrations | |||||
AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | Under Development | 0.6 | KE:757 | Hippocampal anatomy, Altered |
KE:402 | Cognitive function, decreased | |||||
KE:756 | Hippocampal gene expression, Altered | |||||
AOP:302 | Lung surfactant function inhibition leading to decreased lung function | Respiratory System Disease | Under Development | 0.2 | KE:1250 | Decrease, Lung function |
AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | 0.57 | KE:1115 | Increase, Reactive oxygen species |
KE:870 | Increase, Cell Proliferation | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1670 | Lung cancer | |||||
AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive System Disease | - | 0.6 | KE:1757 | Reduce, Sperm count |
KE:155 | Inadequate DNA repair | |||||
KE:1365 | Increase, Apoptosis | |||||
AOP:323 | PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone | Unclassified | - | 0.5 | KE:2147 | Decreased, Viable Offspring |
KE:807 | Decreased, cholesterol | |||||
KE:1758 | Impaired, Spermatogenesis | |||||
AOP:347 | Toll-like receptor 4 activation and peroxisome proliferator-activated receptor gamma inactivation leading to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | - | 0.33 | KE:1283 | Activation, TGF-beta pathway |
KE:1292 | Activation, JNK | |||||
KE:1458 | Pulmonary fibrosis | |||||
AOP:382 | Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:68 | Accumulation, Collagen | |||||
KE:1276 | Lung fibrosis | |||||
AOP:384 | Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease | Urinary System Disease | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1603 | Chronic kidney disease | |||||
AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive Disorder | - | 0.4 | KE:386 | Decrease of neuronal network function |
KE:402 | Cognitive function, decreased | |||||
AOP:406 | SARS-CoV-2 infection leading to hyperinflammation | Unclassified | - | 0.33 | KE:1868 | Hyperinflammation |
KE:1869 | Diminished protective oxidative stress response | |||||
AOP:414 | Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathway | Musculoskeletal System Disease; Respiratory System Disease | - | 0.4 | KE:1276 | Lung fibrosis |
KE:1920 | Altered gene expression, TGF-β dependent fibrosis pathway | |||||
AOP:415 | Aryl hydrocarbon receptor activation leading to lung fibrosis through IL-6 toxicity pathway | Musculoskeletal System Disease; Respiratory System Disease | - | 0.2 | KE:1276 | Lung fibrosis |
AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1670 | Lung cancer | |||||
AOP:417 | Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway | Cancer | - | 0.2 | KE:1670 | Lung cancer |
AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory System Disease | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1250 | Decrease, Lung function | |||||
AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory System Disease | - | 0.5 | KE:1250 | Decrease, Lung function |
KE:1262 | Apoptosis | |||||
AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.5 | KE:870 | Increase, Cell Proliferation |
KE:1670 | Lung cancer | |||||
AOP:431 | Increased tumor necrosis factor (TNF) leading to increased risk of gestational diabetes mellitus (GDM) | Inherited Metabolic Disorder | - | 0.4 | KE:1953 | Gestational diabetes mellitus |
KE:1952 | Abnormal, Glucose homeostasis | |||||
AOP:433 | hERG channel blockade leading to sudden cardiac death | Cardiovascular System Disease | - | 0.67 | KE:1961 | Prolongation of Action Potential Duration |
KE:1962 | Prolongation of QT interval | |||||
KE:1963 | Torsades de Pointes | |||||
KE:1964 | Sudden cardiac death | |||||
AOP:434 | CYP26 inhibition leading to disturbed dorsal lateral hinge point bending which causes neural tube closure defects | Neural Tube Defect | - | 0.11 | KE:10057 | Neural tube closure defect |
AOP:437 | Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity | Urinary System Disease | Under Development | 0.8 | KE:177 | Mitochondrial dysfunction |
KE:709 | Increase, Cytotoxicity (renal tubular cell) | |||||
KE:1392 | Oxidative Stress | |||||
KE:814 | Occurrence, Kidney toxicity | |||||
AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic Disease; Cancer | Under Development | 0.56 | KE:1262 | Apoptosis |
KE:149 | Increase, Inflammation | |||||
KE:1971 | Increased, tumor growth | |||||
KE:1241 | Increased, Motility | |||||
KE:1982 | metastatic breast cancer | |||||
AOP:440 | Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia | Benign Neoplasm; Endocrine System Disease; Reproductive System Disease; Reproductive System Disease; Cancer; Endocrine System Disease | Under Development | 0.11 | KE:2092 | Promotion, Ovarian Cancer |
AOP:442 | Binding to voltage gate sodium channels during development leads to cognitive impairment | Cognitive Disorder | Under Review | 0.29 | KE:757 | Hippocampal anatomy, Altered |
KE:402 | Cognitive function, decreased | |||||
AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic Disease; Cancer | Under Development | 0.3 | KE:1554 | Increase Chromosomal Aberrations |
KE:155 | Inadequate DNA repair | |||||
KE:1982 | metastatic breast cancer | |||||
AOP:449 | Ceramide synthase inhibition leading to neural tube defects | Neural Tube Defect | - | 0.14 | KE:1561 | Neural tube defects |
AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | 0.44 | KE:1115 | Increase, Reactive oxygen species |
KE:870 | Increase, Cell Proliferation | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1670 | Lung cancer | |||||
AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory System Disease | - | 0.36 | KE:2011 | Emphysema |
KE:2008 | Chronic obstructive pulmonary disease | |||||
KE:1262 | Apoptosis | |||||
KE:1392 | Oxidative Stress | |||||
AOP:455 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development | Musculoskeletal System Disease | Under Review | 0.5 | KE:2020 | Decrease, sox9 expression |
KE:947 | Increase, Early Life Stage Mortality | |||||
KE:2021 | Increase, slincR expression | |||||
AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | 0.67 | KE:2020 | Decrease, sox9 expression |
KE:317 | Altered, Cardiovascular development/function | |||||
KE:947 | Increase, Early Life Stage Mortality | |||||
KE:2021 | Increase, slincR expression | |||||
AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited Metabolic Disorder | - | 0.5 | KE:281 | Thyroxine (T4) in serum, Decreased |
KE:2119 | Insulin resistance, increased | |||||
KE:1392 | Oxidative Stress | |||||
AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.38 | KE:402 | Cognitive function, decreased |
KE:281 | Thyroxine (T4) in serum, Decreased | |||||
KE:756 | Hippocampal gene expression, Altered | |||||
AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.56 | KE:281 | Thyroxine (T4) in serum, Decreased |
KE:850 | Induction, CYP1A2/CYP1A5 | |||||
KE:1392 | Oxidative Stress | |||||
KE:402 | Cognitive function, decreased | |||||
KE:756 | Hippocampal gene expression, Altered | |||||
AOP:464 | Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits | Nervous System Disease | - | 0.21 | KE:177 | Mitochondrial dysfunction |
KE:389 | Increased, Intracellular Calcium overload | |||||
KE:896 | Parkinsonian motor deficits | |||||
KE:1392 | Oxidative Stress | |||||
AOP:468 | Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death) | Unclassified | - | 0.25 | KE:1868 | Hyperinflammation |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | 0.2 | KE:885 | Increase, Cancer |
AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental Disorder Of Mental Health | Under Development | 0.38 | KE:389 | Increased, Intracellular Calcium overload |
KE:341 | Impairment, Learning and memory | |||||
KE:386 | Decrease of neuronal network function | |||||
AOP:482 | Deposition of energy leading to occurrence of bone loss | Musculoskeletal System Disease | Under Review | 0.29 | KE:2091 | Occurrence, Bone Loss |
KE:1392 | Oxidative Stress | |||||
AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental Disorder Of Mental Health | Under Review | 0.38 | KE:2244 | Altered Stress Response Signaling |
KE:341 | Impairment, Learning and memory | |||||
KE:1392 | Oxidative Stress | |||||
AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive Disorder | - | 0.14 | KE:402 | Cognitive function, decreased |
AOP:486 | Binding to the extracellular protein laminin leading to decreased cognitive function | Cognitive Disorder | - | 0.14 | KE:402 | Cognitive function, decreased |
AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental Disorder Of Mental Health | - | 0.27 | KE:2121 | decreased, Intellectual Quotient |
KE:188 | Neuroinflammation | |||||
KE:341 | Impairment, Learning and memory | |||||
AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired Metabolic Disease | - | 0.3 | KE:2129 | Metabolically unhealthy Obesity |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:2119 | Insulin resistance, increased | |||||
AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive System Disease; Cancer | - | 0.44 | KE:286 | Altered, Transcription of genes by the androgen receptor |
KE:854 | Alterations, Cellular proliferation / hyperplasia | |||||
KE:1183 | Decreased, Apoptosis (Epithelial Cells) | |||||
KE:2135 | Prostate cancer | |||||
AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited Metabolic Disorder; Disease Of Metabolism | - | 0.62 | KE:2145 | Metabolic syndrome |
KE:1392 | Oxidative Stress | |||||
KE:177 | Mitochondrial dysfunction | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:2119 | Insulin resistance, increased | |||||
AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous System Disease | - | 0.5 | KE:191 | Neuronal dysfunction |
KE:2150 | Neurological disorder | |||||
AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous System Disease | - | 0.75 | KE:386 | Decrease of neuronal network function |
KE:2150 | Neurological disorder | |||||
KE:1392 | Oxidative Stress | |||||
AOP:519 | Cardiac ion channels blockade leading to increased incidence of cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.75 | KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population |
KE:1961 | Prolongation of Action Potential Duration | |||||
KE:2283 | Increased the early premature depolarizations during repolarization | |||||
AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.2 | KE:341 | Impairment, Learning and memory |
AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.08 | KE:341 | Impairment, Learning and memory |
AOP:532 | Retinoic acid receptor agonism during cerebellar development leading to impaired locomotor function | Unclassified | - | 0.4 | KE:2229 | Cerebellar neuronal differentiation. Decreased |
KE:2231 | Locomotor function. Impaired | |||||
AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.5 | KE:386 | Decrease of neuronal network function |
KE:341 | Impairment, Learning and memory | |||||
KE:1239 | Altered, Gene Expression | |||||
AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | 0.67 | KE:1115 | Increase, Reactive oxygen species |
KE:885 | Increase, Cancer | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
KE:1392 | Oxidative Stress | |||||
AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental Disorder Of Mental Health | - | 0.78 | KE:389 | Increased, Intracellular Calcium overload |
KE:2233 | Decreased, ERαβ heterodimers | |||||
KE:1262 | Apoptosis | |||||
KE:1392 | Oxidative Stress | |||||
KE:188 | Neuroinflammation | |||||
KE:341 | Impairment, Learning and memory | |||||
KE:2151 | Disruption, neurotransmitter release | |||||
AOP:539 | Decreased Sodium/Potassium ATPase activity leads to Heart failure | Cardiovascular System Disease | - | 0.29 | KE:2261 | Decreased, blood plasma volume |
KE:1535 | Heart failure | |||||
AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | 0.2 | KE:885 | Increase, Cancer |
AOP:551 | Increased Muscarinic M2 Receptor leading to Arrhythmia | Symptom | - | 0.2 | KE:1106 | Occurrence, cardiac arrhythmia |
AOP:553 | Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure | Cardiovascular System Disease | - | 0.5 | KE:698 | Altered, Action Potential |
KE:1535 | Heart failure | |||||
AOP:554 | β-adrenergic receptor agonists leading to arrhythmias. | Symptom | - | 0.25 | KE:1106 | Occurrence, cardiac arrhythmia |
AOP:556 | Decreased Na/K ATPase activity leading to heart failure | Cardiovascular System Disease | - | 0.33 | KE:389 | Increased, Intracellular Calcium overload |
KE:1535 | Heart failure | |||||
AOP:558 | Phosphodiesterase inhibition leading to heart failure | Cardiovascular System Disease | - | 0.33 | KE:389 | Increased, Intracellular Calcium overload |
KE:1535 | Heart failure | |||||
AOP:559 | Inhibition of acetylcholinesterase (AChE) leading to arrhythmias | Symptom | - | 0.4 | KE:698 | Altered, Action Potential |
KE:1106 | Occurrence, cardiac arrhythmia | |||||
AOP:562 | HCN Channel Inhibition leading to Arrhythmias | Symptom | - | 0.6 | KE:1106 | Occurrence, cardiac arrhythmia |
KE:2291 | Slowed Heart Rate | |||||
KE:2292 | Altered Cardiac Electrical Conduction | |||||
AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental Disorder Of Mental Health | - | 0.5 | KE:2121 | decreased, Intellectual Quotient |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:2195 | Increase, CNS Neural cell death | |||||
AOP:572 | Imidacloprid-Induced BMP4 inhibition Leading to Neural Tube Closure Defects | Neural Tube Defect | - | 0.2 | KE:1561 | Neural tube defects |
AOP:573 | Inhibition, cytochrome oxidase leads to Increased, pulmonary edema | Respiratory System Disease | - | 0.33 | KE:2316 | Increased, pulmonary edema |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:8 | Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Nervous System Disease | Under Development | 0.44 | KE:757 | Hippocampal anatomy, Altered |
KE:281 | Thyroxine (T4) in serum, Decreased | |||||
KE:239 | Activation, Pregnane-X receptor, NR1l2 | |||||
KE:756 | Hippocampal gene expression, Altered | |||||
AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal System Disease | Under Development | 0.5 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:288 | Activation of specific nuclear receptors, Transcriptional change | |||||
KE:41 | Inhibition, Bile Salt Export Pump (ABCB11) | |||||
AOP:38 | Protein Alkylation leading to Liver Fibrosis | Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.43 | KE:68 | Accumulation, Collagen |
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:244 | Alkylation, Protein | |||||
AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal System Disease | Under Review | 0.8 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis | |||||
KE:165 | Activation, Long term AHR receptor driven direct and indirect gene expression changes | |||||
KE:139 | N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects | |||||
AOP:60 | NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.58 | KE:245 | Activation, PXR/SXR |
KE:54 | Up Regulation, CD36 | |||||
KE:454 | Increased, Triglyceride formation | |||||
KE:471 | Inhibition, FoxA2 | |||||
KE:462 | Up Regulation, SCD-1 | |||||
KE:474 | Down Regulation, HMGCS2 | |||||
KE:472 | Down Regulation, CPT1A | |||||
AOP:62 | AKT2 activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.5 | KE:484 | Activation, AKT2 |
KE:486 | systemic inflammation leading to hepatic steatosis | |||||
AOP:69 | Modulation of Adult Leydig Cell Function Subsequent to Decreased Cholesterol Synthesis or Transport in the Adult Leydig Cell | Reproductive System Disease | - | 0.4 | KE:645 | Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells |
KE:642 | Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol | |||||
AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.5 | KE:786 | Increase, Cytotoxicity (hepatocytes) |
KE:787 | Increase, Regenerative cell proliferation (hepatocytes) | |||||
AOP:121 | Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) | Cancer; Urinary System Disease | - | 0.4 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
KE:793 | Increase, Urinary bladder calculi | |||||
AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive System Disease; Cancer | - | 0.57 | KE:1064 | prepubertal increase, Estrogen receptor (ER) activity |
KE:1066 | Promotion, SIX-1 postive basal-type progenitor cells | |||||
KE:1067 | Proliferation/Clonal Expansion, aberrant basal cells | |||||
KE:1069 | Increased, Hyperplasia (glandular epithelial cells of endometrium) | |||||
AOP:201 | Juvenile hormone receptor agonism leading to male offspring induction associated population decline | Unclassified | - | 0.33 | KE:1206 | Induction, Doublesex1 gene |
KE:1205 | Activation, Juvenile hormone receptor | |||||
AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive System Disease | - | 0.75 | KE:1262 | Apoptosis |
KE:177 | Mitochondrial dysfunction | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1174 | Activation, NADPH Oxidase | |||||
KE:1281 | Increased, DNA Damage-Repair | |||||
KE:1279 | Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK | |||||
AOP:209 | Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP | Gastrointestinal System Disease | - | 0.38 | KE:1287 | Glutathione synthesis |
KE:1286 | Down Regulation, GSS and GSTs gene | |||||
KE:1284 | Up Regulation, SREBF2 | |||||
AOP:282 | Adverse outcome pathway on photochemical toxicity initiated by light exposure | Unclassified | Under Review | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:298 | Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer via chronic ROS | Cancer; Gastrointestinal System Disease | Under Review | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1753 | Chronic reactive oxygen species | |||||
AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1769 | Increase, Body fluid overload | |||||
AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
AOP:329 | Excessive reactive oxygen species production leading to mortality (3) | Unclassified | - | 0.6 | KE:1115 | Increase, Reactive oxygen species |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
KE:1445 | Increase, Lipid peroxidation | |||||
AOP:330 | Excessive reactive oxygen species production leading to mortality (4) | Unclassified | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1365 | Increase, Apoptosis | |||||
AOP:335 | AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment | Cancer; Urinary System Disease | - | 0.4 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
KE:177 | Mitochondrial dysfunction | |||||
AOP:423 | Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway | Unclassified | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:177 | Mitochondrial dysfunction | |||||
AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory System Disease | - | 0.6 | KE:1262 | Apoptosis |
KE:1458 | Pulmonary fibrosis | |||||
KE:149 | Increase, Inflammation | |||||
KE:1392 | Oxidative Stress | |||||
KE:1445 | Increase, Lipid peroxidation | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:165 | Activation, Long term AHR receptor driven direct and indirect gene expression changes | |||||
KE:1250 | Decrease, Lung function | |||||
KE:1239 | Altered, Gene Expression | |||||
KE:1993 | Increase, Pneumonia | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1198 | Activation, Macrophages | |||||
AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal System Disease | - | 0.31 | KE:1995 | Abnormal lipid metabolism |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1198 | Activation, Macrophages | |||||
KE:1392 | Oxidative Stress | |||||
AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal System Disease | - | 0.55 | KE:1262 | Apoptosis |
KE:1392 | Oxidative Stress | |||||
KE:149 | Increase, Inflammation | |||||
KE:177 | Mitochondrial dysfunction | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:898 | Disruption, Lysosome | |||||
AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal System Disease | - | 0.31 | KE:1995 | Abnormal lipid metabolism |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1198 | Activation, Macrophages | |||||
KE:1392 | Oxidative Stress | |||||
AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1262 | Apoptosis | |||||
KE:2040 | Decrease, GLI1/2 target gene expression | |||||
AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular System Disease | - | 0.19 | KE:1115 | Increase, Reactive oxygen species |
KE:177 | Mitochondrial dysfunction | |||||
KE:1392 | Oxidative Stress | |||||
AOP:517 | Pregnane X Receptor (PXR) activation leads to liver steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.4 | KE:54 | Up Regulation, CD36 |
KE:239 | Activation, Pregnane-X receptor, NR1l2 | |||||
AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.56 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:1262 | Apoptosis | |||||
KE:1392 | Oxidative Stress | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:285 | Reduction, Vitellogenin synthesis in liver | |||||
AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular System Disease | - | 0.38 | KE:1392 | Oxidative Stress |
KE:1816 | Mitochondrial dysfunction EMPTY | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:1198 | Activation, Macrophages | |||||
AOP:545 | Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased cholesterol synthesis | Unclassified | - | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
AOP:548 | Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased PCSK9 protein expression | Unclassified | - | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:95 | Ether-a-go-go (ERG) voltage-gated potassium channel inhibition leading to reduced survival | Unclassified | - | 0.33 | KE:592 | Reduced, survival |
KE:593 | Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel | |||||
AOP:257 | Receptor mediated endocytosis and lysosomal overload leading to kidney toxicity | Urinary System Disease | Under Development | 1.0 | KE:831 | Disturbance, Lysosomal function |
KE:814 | Occurrence, Kidney toxicity | |||||
KE:1486 | Binding of substrate, endocytic receptor | |||||
KE:898 | Disruption, Lysosome | |||||
KE:709 | Increase, Cytotoxicity (renal tubular cell) | |||||
AOP:258 | Renal protein alkylation leading to kidney toxicity | Urinary System Disease | Under Development | 1.0 | KE:244 | Alkylation, Protein |
KE:814 | Occurrence, Kidney toxicity | |||||
KE:177 | Mitochondrial dysfunction | |||||
KE:40 | Decrease, Mitochondrial ATP production | |||||
KE:709 | Increase, Cytotoxicity (renal tubular cell) | |||||
AOP:261 | L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility | Cardiovascular System Disease | Under Development | 0.25 | KE:1529 | Blockade, L-Type Calcium Channels |
KE:1535 | Heart failure | |||||
AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | 1.0 | KE:1821 | Decrease, Cell proliferation |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
KE:1521 | Decrease, Growth | |||||
AOP:264 | Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death | Unclassified | Under Development | 0.75 | KE:1771 | Decrease, Adenosine triphosphate pool |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
KE:1521 | Decrease, Growth | |||||
AOP:265 | Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium | Unclassified | Under Development | 0.5 | KE:1521 | Decrease, Growth |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:266 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity | Unclassified | Under Development | 0.5 | KE:1771 | Decrease, Adenosine triphosphate pool |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
KE:1521 | Decrease, Growth | |||||
AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.6 | KE:1821 | Decrease, Cell proliferation |
KE:1521 | Decrease, Growth | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:268 | Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling | Unclassified | Under Development | 0.5 | KE:1521 | Decrease, Growth |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:324 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death | Unclassified | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:1521 | Decrease, Growth | |||||
AOP:325 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death | Unclassified | - | 0.75 | KE:1115 | Increase, Reactive oxygen species |
KE:1521 | Decrease, Growth | |||||
KE:1445 | Increase, Lipid peroxidation | |||||
AOP:326 | Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell death | Unclassified | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:1521 | Decrease, Growth | |||||
AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1521 | Decrease, Growth | |||||
AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | 0.8 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1521 | Decrease, Growth | |||||
KE:1445 | Increase, Lipid peroxidation | |||||
AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 1.0 | KE:1521 | Decrease, Growth |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
KE:1821 | Decrease, Cell proliferation | |||||
AOP:392 | Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation | Unclassified | Under Development | 0.6 | KE:1868 | Hyperinflammation |
KE:1867 | Bradykinin system, hyperactivated | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:411 | Oxidative stress Leading to Decreased Lung Function | Respiratory System Disease | - | 0.5 | KE:1250 | Decrease, Lung function |
KE:1392 | Oxidative Stress | |||||
AOP:424 | Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction | Respiratory System Disease | - | 0.33 | KE:1250 | Decrease, Lung function |
KE:1392 | Oxidative Stress | |||||
AOP:425 | Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1 | Respiratory System Disease | - | 0.33 | KE:1250 | Decrease, Lung function |
KE:1392 | Oxidative Stress | |||||
AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.5 | KE:1392 | Oxidative Stress |
KE:177 | Mitochondrial dysfunction | |||||
KE:1919 | Increased, Cardiac Dysregulation | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population | |||||
KE:1924 | Increased,Cardiac fibrosis | |||||
AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary System Disease | - | 0.5 | KE:1365 | Increase, Apoptosis |
KE:1392 | Oxidative Stress | |||||
KE:814 | Occurrence, Kidney toxicity | |||||
KE:177 | Mitochondrial dysfunction | |||||
KE:759 | Increased, Kidney Failure | |||||
KE:1097 | Occurrence, renal proximal tubular necrosis | |||||
AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.41 | KE:2001 | Cardiac hypertrophy |
KE:1392 | Oxidative Stress | |||||
KE:1443 | Atherosclerosis | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population | |||||
KE:1924 | Increased,Cardiac fibrosis | |||||
KE:1198 | Activation, Macrophages | |||||
AOP:472 | DNA adduct formation leading to kidney failure | Urinary System Disease | - | 0.67 | KE:1392 | Oxidative Stress |
KE:149 | Increase, Inflammation | |||||
KE:1816 | Mitochondrial dysfunction EMPTY | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:759 | Increased, Kidney Failure | |||||
KE:1097 | Occurrence, renal proximal tubular necrosis | |||||
AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive Disorder | - | 0.57 | KE:1115 | Increase, Reactive oxygen species |
KE:1869 | Diminished protective oxidative stress response | |||||
KE:402 | Cognitive function, decreased | |||||
KE:1392 | Oxidative Stress | |||||
AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental Disorder Of Mental Health | - | 1.0 | KE:2146 | Activation of mitogen-activated protein kinase kinase, extracellular signal-regulated kinase 1/2 |
KE:1339 | Increase, intracellular calcium | |||||
KE:341 | Impairment, Learning and memory | |||||
KE:2151 | Disruption, neurotransmitter release | |||||
AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental Disorder Of Mental Health | - | 1.0 | KE:1262 | Apoptosis |
KE:2146 | Activation of mitogen-activated protein kinase kinase, extracellular signal-regulated kinase 1/2 | |||||
KE:177 | Mitochondrial dysfunction | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:352 | N/A, Neurodegeneration | |||||
KE:1339 | Increase, intracellular calcium | |||||
KE:341 | Impairment, Learning and memory | |||||
AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | 0.8 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:885 | Increase, Cancer | |||||
KE:1392 | Oxidative Stress | |||||
AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | 0.6 | KE:1115 | Increase, Reactive oxygen species |
KE:1060 | Alteration, lipid metabolism | |||||
KE:885 | Increase, Cancer | |||||
AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | 1.0 | KE:1392 | Oxidative Stress |
KE:1758 | Impaired, Spermatogenesis | |||||
KE:1445 | Increase, Lipid peroxidation | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:2147 | Decreased, Viable Offspring | |||||
KE:2206 | Increased, histomorphological alteration of testis | |||||
KE:2205 | Increased, essential element imbalance | |||||
AOP:550 | Increased LMNA gene mutation leading to heart failure | Cardiovascular System Disease | - | 1.0 | KE:2066 | Altered Signaling Pathways |
KE:2279 | Structural changes in lamin A/C | |||||
KE:2278 | Increased LMNA Mutation | |||||
KE:1535 | Heart failure | |||||
KE:1924 | Increased,Cardiac fibrosis | |||||
AOP:552 | Inhibiton of L-Type Calcium Channels leading to heart failure via QT interval prolongation and Torsades de Pointes (TdP) | Cardiovascular System Disease | - | 1.0 | KE:698 | Altered, Action Potential |
KE:2281 | Increased uncoordinated cardiac contraction | |||||
KE:1529 | Blockade, L-Type Calcium Channels | |||||
KE:1963 | Torsades de Pointes | |||||
KE:1535 | Heart failure | |||||
KE:1962 | Prolongation of QT interval | |||||
AOP:555 | Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure | Cardiovascular System Disease | - | 1.0 | KE:2283 | Increased the early premature depolarizations during repolarization |
KE:1961 | Prolongation of Action Potential Duration | |||||
KE:593 | Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel | |||||
KE:1535 | Heart failure | |||||
KE:1962 | Prolongation of QT interval | |||||
AOP:560 | Inhibition of Funny current (If) leading to Arrhythmias | Symptom | - | 1.0 | KE:1106 | Occurrence, cardiac arrhythmia |
KE:2290 | Inhibition of Funny current (If) | |||||
KE:2291 | Slowed Heart Rate | |||||
KE:2292 | Altered Cardiac Electrical Conduction |
TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.